李月平

• 1:国家放射与治疗临床医学研究中心
• 2:苏州工业园区东方华夏心血管健康研究院高血压介入治疗工作委员会
• 3:《经皮去肾神经术治疗高血压临床路径中国专家共识(2025版)》专家组
• 4:首都医科大学附属北京安贞医院

摘要(Abstract)：

经皮去肾神经术（RDN）作为微创介入治疗高血压的方法，已经在国内外应用于临床，主要用于难治性高血压或不耐受降压药物的高血压患者。现有的临床研究证实了该技术的安全性和有效性。鉴于RDN技术处于推广、普及阶段，为推动这项技术在临床有序开展，规范操作流程和诊疗行为，专家组撰写此临床路径，详细介绍患者临床评估（适应证、禁忌证及患者筛选流程）、RDN手术规范化操作流程（围术期药物、麻醉、消融、并发症处理等）以及术后随访计划（随访内容、方式、时间节点等），希望能为从事RDN临床工作的医师提供参考，规范诊疗行为，推动RDN学科规范、精准、持续发展。

关键词(KeyWords)： 经皮去肾神经术;高血压;临床路径;专家共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李月平

参考文献(References)：

• [1] Mann SJ.Neurogenic hypertension:pathophysiology,diagnosis and management[J].Clin Auton Res,2018,28(4):363-374.DOI:10.1007/s10286-018-0541-z.
• [2] Townsend RR,Mahfoud F,Kandzari DE,et al.Catheterbased renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTNOFF MED):a randomised,sham-controlled,proof-ofconcept trial[J].Lancet,2017,390(10108):2160-2170.DOI:10.1016/S0140-6736(17)32281-X.
• [3] Kandzari DE,B?hm M,Mahfoud F,et al.Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J].Lancet,2018,391(10137):2346-2355.DOI:10.1016/S0140-6736(18)30951-6.
• [4]Azizi M,Schmieder RE,Mahfoud F,et al.Endovascular ultrasound renal denervation to treat hypertension(RADIANCE-HTN SOLO):a multicentre,international,single-blind,randomized,sham-controlled trial[J].Lancet,2018,391(10137):2335-2345.DOI:10.1016/S0140-6736(18)31082-1.
• [5] B?hm M,Kario K,Kandzari DE,et al.Efficacy of catheter based renal denervation in the absence of antihypertensive medications(SPYRAL HTN-OFF MED Pivotal):a multicentre,randomised,sham-controlled trial[J].Lancet,2020,395(10234):1444-1451.DOI:10.1016/S0140-6736(20)30554-7.
• [6]Azizi M,Sanghvi K,Saxena M,et al.Ultrasound renal denervation for hypertension resistant to a triple medication pill(RADIANCE-HTN TRIO):a randomised,multicentre,single-blind,sham-controlled trial[J].Lancet,2021,397(10293):2476-2486.DOI:10.1016/S0140-6736(21)00788-1.
• [7] Kandzari DE,Townsend RR,Kario K,et al.Safety and efficacy of renal denervation in patients taking antihypertensive medications[J].J Am Coll Cardiol,2023,82(19):1809-1823.DOI:10.1016/j.jacc.2023.08.045.
• [8]Wang J,Yin Y,Lu C,et al.Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension(SMART):6-month follow-up of a randomised,controlled trial[J].EClinicalMedicine,2024,72:102626.DOI:10.1016/j.eclinm.2024.102626.
• [9]Li Y,Gao F,Ren C,et al.The Netrod~(TM)six-electrode radiofrequency renal denervation system for uncontrolled hypertension:a sham-controlled trial[J].Eur Heart J,2024,45(44):4761-4764.DOI:10.1093/eurheartj/ehae703.
• [10]Jiang X,Mahfoud F,Li W,et al.Efficacy and safety of catheterbased radiofrequency renal denervation in Chinese patients with uncontrolled hypertension:the randomized,sham-controlled,multi-center Iberis-HTN trial[J].Circulation,2024,150(20):1588-1598.DOI:10.1161/CIRCULATIONAHA.124.069215.
• [11] Kario K,Kim BK,Aoki J,et al.Renal denervation in Asia:consensus statement of the Asia Renal Denervation Consortium[J].Hypertension,2020,75(3):590-602.DOI:10.116 1/HYPERTENSIONAHA.119.1367 1.
• [12]Kandzari DE,Townsend RR,Bakris G,et al.Renal denervation in hypertension patients:proceedings from an expert consensus roundtable cosponsored by SCAI and NKF[J].Catheter Cardiovasc Interv,2021,98(3):416-426.DOI:10.1002/ccd.29884.
• [13]Wang TD,Chiang CE,Chao TH,et al.2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension[J].Acta Cardiol Sin,2022,38(3):225-325.DOI:10.6515/ACS.202205 38(3).20220321A.
• [14]李月平,卢成志,蒋雄京,等.经皮去肾神经术治疗高血压中国专家科学声明[J].中国介入心脏病学杂志,2023,31(12):881-893.DOI:10.3969/j.issn.1004-8812.2023.12.001.
• [15] Barbato E,Azizi M,Schmieder RE,et al.Renal denervation in the management of hypertension in adults.A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur Heart J,2023,44(15):1313-1330.DOI:10.1093/eurheartj/ehad054.
• [16]Zeijen VJM,Kroon AA,van den Born BH,et al.The position of renal denervation in treatment of hypertension:an expert consensus statement[J].Neth Heart J,2023,31(1):3-11.DOI:10.1007/s12471-022-01717-4.
• [17]Mancia G,Kreutz R,Brunstr?m M,et al.2023 ESH Guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension:endorsed by the International Society of Hypertension(ISH)and the European Renal Association(ERA)[J].J Hypertens,2023,41(12):1874-2071.DOI:10.1097/HJH.0000000000003480.
• [18]中国高血压防治指南修订委员会,高血压联盟(中国),中国医疗保健国际交流促进会高血压病学分会,等.中国高血压防治指南(2024年修订版)[J].中华高血压杂志,2024,32(7):603-700.DOI:10.16439/j.issn.1673-7245.2024.07.002.
• [19]Zweiker D,Koppelst?tter C,Hohenstein K,et al.Renal sympathetic denervation 2024 in Austria:recommendations from the Austrian Society of Hypertension:endorsed by the Austrian Society of Nephrology and the Working Group of Interventional Cardiology of the Austrian Society of Cardiology[J].Wien Klin Wochenschr,2024,136(Suppl 14):559-569.DOI:10.1007/s00508-024-02440-3.
• [20] Cluett JL,Blazek O,Brown AL,et al.Renal denervation for the treatment of hypertension:a scientific statement from the American Heart Association[J].Hypertension,2024,81(10):e13 5-e148.DOI:10.1161/HYP.0000000000000240.
• [21]Pathak A,Boulestreau R,Sapoval M,et al.Catheter-based renal denervation in the treatment of arterial hypertension:an expert consensus statement on behalf of the French Society of Hypertension(SFHTA),French Society of Radiology(SFR),French Society of Interventional Cardiology(GACI),French Society of Cardiology(SFC),French Association of Private Cardiologists(CNCF),French Association of Hospital Cardiologists(CNCH),French Society of Thoracic and Cardiovascular Surgery(SFCTCV)and French Society of Vascular and Endovascular Surgery(SCVE)[J].Arch Cardiovasc Dis,2024,117(10):601-611.DOI:10.1016/j.acvd.2024.05.122.
• [22]Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESC Guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J].JHypertens,2013,31(7):1281-1357.DOI:10.1097/01.hj h.0000431740.32696.cc.
• [23]Calhoun DA,Jones D,Textor S,et al.Resistant hypertension:diagnosis,evaluation,and treatment:a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J].Circulation,2008,117(25):e510-e526.DOI:10.1161/CIRCULATIONAHA.108.189141.
• [24]Faselis C,Doumas M,Papademetriou V.Common secondary causes of resistant hypertension and rational for treatment[J].Int J Hypertens,2011,2011:236239.DOI:10.4061/2011/23623 9.
• [25]中国医药教育协会心血管内科专业委员会,中国医师协会高血压专业委员会,中华医学会心血管病学分会高血压学组.中国继发性高血压临床筛查多学科专家共识(2023)[J].心脑血管病防治,2023,23(1):1-24.DOI:10.3969/j.issn.1009-816x.2023.01.001.
• [26]中国医师协会内分泌代谢科医师分会,中国内分泌性高血压协作组.内分泌性高血压筛查专家共识(2025版)[J].中华内科杂志,2025,64(4):288-301.DOI:10.3760/cma.j.cn112138-20250103-00007.
• [27]Fengler K,Rommel KP,Blazek S,et al.A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension(RADIO SOUND-HTN)[J].Circulation,2019,139(5):590-600.DOI:10.1161/CIRCULATIONAHA.118.037654.
• [28]Mahfoud F,Kandzari DE,Kario K,et al.Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs(SPYRAL HTN-ON MED):a randomised,shamcontrolled trial[J].Lancet,2022,399(10333):1401-1410.DOI:10.1016/S0140-6736(22)00455-X.
• [29]Bhatt DL,Vaduganathan M,Kandzari DE,et al.Long-term outcomes after catheter-based renal artery denervation for resistant hypertension:final follow-up of the randomised SYMPLICITY HTN-3 Trial[J].Lancet,2022,400(10361):1405-1416.DOI:10.1016/S0140-6736(22)01787-1.
• [30]Rader F,Kirtane AJ,Wang Y,et al.Durability of blood pressure reduction after ultrasound renal denervation:three-year follow-up of the treatment arm of the randomised RADIANCEHTN SOLO trial[J].EuroIntervention,2022,18(8):e677-e685.DOI:10.4244/EIJ-D-22-00305.
• [31]Al G ho rani H,Kulenthiran S,Recktenwald MJM,et al.10-year outcomes of catheter-based renal denervation in patients with resistant hypertension[J].J Am Coll Cardiol,2023,81(5):517-519.DOI:10.1016/j.jacc.2022.11.038
• [32]Sanders MF,Reitsma JB,Morpey M,et al.Renal safety of catheter-based renal denervation:systematic review and metaanalysis[J].Nephrol Dial Transplant,2017,32(9):1440-1447.DOI:10.1093/ndt/gfx088.
• [33]Mahfoud F,B?hm M,Schmieder R,et al.Effects of renal denervation on kidney function and long-term outcomes:3-year follow-up from the Global SYMPLICITY Registry[J].Eur Heart J,2019,40(42):3474-3482.DOI:10.1093/eurheartj/ehz118.
• [34]Mahfoud F,Mancia G,Schmieder RE,et al.Outcomes following radiofrequency renal denervation according to antihypertensivemedications:subgroup analysis of the Global SYMPLICITY Registry DEFINE[J].Hypertension,2023,80(8):1759-1770.DOI:10.1161/HYPERTENSIONAHA.123.21283.
• [35] Townsend RR,Walton A,Hettrick DA,et al.Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation[J].Euro Intervention,2020,16(1):89-96.DOI:10.4244/EIJ-D-19-00902.
• [36] Ott C,Mahfoud F,Mancia G,et al.Renal denervation in patients with versus without chronic kidney disease:results from the Global SYMPLICITY Registry with follow-up data of 3 years[J].Nephrol Dial Transplant,2022,37(2):304-310.DOI:10.1093/ndt/gfab154.
• [37]Fengler K,Reimann P,Rommel KP,et al.Comparison of long-term outcomes for responders versus non-responders following renal denervation in resistant hypertension[J].J Am Heart Assoc,2021,10(21):e022429.DOI:10.1161/JAHA.121.022429.
• [38] Schmieder RE,Mahfoud F,Mancia G,et al.Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry[J].Eur Heart J Qual Care Clin Outcomes,2023,9(6):575-582.DOI:10.1093/ehjqcco/qcac056.
• [39]杜小宇,卢成志.经导管射频消融经皮去肾神经术治疗高血压的长期疗效分析[J].中国介入心脏病学杂志,2024,32(6):324-329.DOI:10.3969/j.issn.1004-8812.2024.06.005.
• [40]Haider SA,Wagener M,Iqbal T,et al.Does renal denervation require cardiovascular outcome-driven data?[J].Hypertens Res,2024,47(10):2633-2643.DOI:10.1038/s41440-024-01598-7.